Clinical Trial Update: An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety, tolerability, and immunogenicity of the CMV vaccine ASP0113 in CMV-seropositive and CMV-seronegative healthy subjects and C…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• ASP0113

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Dialysis, Healthy Subjects | Phase 1 | Status: COMPLETED